Skip to main content
. 2023 Jul 7;10:1206279. doi: 10.3389/fcvm.2023.1206279

Figure 3.

Figure 3

EV-CPC treatment improves heart contractility of CCM mice and decrease adverse remodeling. Survival Kaplan Meier curves with Log rank analysis test performed (A) at 3 weeks after the beginning of DOX treatment and (B) at end-of-study. MRI evaluation of cardiac parameters (C-F): (C) CS measured by MRI (Mean + / − SEM) at the basal global, (D) basal endocardial and (E) basal epicardial levels (Sham: n = 14; DOX+Placebo: n = 14, DOX+EV-CPC: n = 11); and (F) GLS (Median +/− IQR) as a percent change from baseline (some mice, two in sham group and one in each EV or placebo group, could not be included into GLS datasets due to unavailable 2-chamber views in MRI: Sham: n = 14; DOX+Placebo: n = 14, DOX+EV-CPC: n = 11). Relative mRNA expression in mouse hearts of Gal3 (G; Mean +/− SEM), Myh6/Myh7 (H; Median +/− IQR) and NPPA (I; Median +/− IQR): these data integrated a supplemental series of Sham and DOX+placebo animals exclusively used for PCR assessment. *p ≤ 0.05; ***p ≤ 0.001. CS, circumferential strain (%); GLS, Global longitudinal strain; Gal 3, galectin 3; Myh6/Myh7 ratio, myosin heavy chain α/myosin heavy chain β; NPPA, Atrial natriuretic peptide.